Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:32 pm Sale |
2022-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
Nextech V Oncology S.C.S. SICAV-SIF | 2,329,480 5.300% |
-678,763 (-22.56%) |
Filing History |
| 2023-02-13 4:21 pm Sale |
2022-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
Vida Ventures LLC | 2,207,772 5.000% |
-539,661 (-19.64%) |
Filing History |
| 2023-02-03 4:27 pm Purchase |
2022-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
BLACKROCK INC BLK |
2,335,818 5.300% |
2,335,818 (New Position) |
Filing History |
| 2023-01-23 4:28 pm Purchase |
2023-01-13 | 13G | Kinnate Biopharma Inc. KNTE |
Lynx1 Capital Management LP | 2,213,178 5.000% |
2,213,178 (New Position) |
Filing History |
| 2022-02-14 4:11 pm Unchanged |
2021-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
RA Capital Management, L.P. | 3,593,052 8.200% |
0 (Unchanged) |
Filing History |
| 2022-02-10 5:17 pm Purchase |
2021-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
Vida Ventures LLC | 2,747,433 6.300% |
359 (+0.01%) |
Filing History |
| 2022-02-09 09:22 am Sale |
2022-02-08 | 13G | Kinnate Biopharma Inc. KNTE |
FMR CORP | 2,092,523 4.788% |
-357,612 (-14.60%) |
Filing History |
| 2021-02-16 4:39 pm Purchase |
2020-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
RA Capital Management, L.P. | 3,593,052 8.300% |
3,593,052 (New Position) |
Filing History |
| 2021-02-16 4:00 pm Purchase |
2020-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
Nextech V Oncology S.C.S. SICAV-SIF | 3,008,243 6.900% |
3,008,243 (New Position) |
Filing History |
| 2021-02-12 5:40 pm Purchase |
2020-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
Vida Ventures LLC | 2,747,074 6.300% |
2,747,074 (New Position) |
Filing History |
| 2021-02-08 10:25 am Purchase |
2021-02-05 | 13G | Kinnate Biopharma Inc. KNTE |
FMR CORP | 2,450,135 5.654% |
2,450,135 (New Position) |
Filing History |
| 2020-12-14 9:24 pm Purchase |
2020-12-03 | 13D | Kinnate Biopharma Inc. KNTE |
Foresite Capital Fund IV, L.P. | 10,838,311 25.000% |
10,838,311 (New Position) |
Filing History |
| 2020-12-11 4:39 pm Purchase |
2020-12-02 | 13D | Kinnate Biopharma Inc. KNTE |
ORBIMED ADVISORS LLC | 3,397,929 7.800% |
3,397,929 (New Position) |
Filing History |